Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLK286 Weekly in Advanced NSCLC
NCT00040638Phase 2Completed
- Sponsor
- Telik, Inc.
- Start
- Jul 2002
- Primary completion
- Aug 2003
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canfosfamide in non-small cell lung cancer (NSCLC), sponsored by Telik, Inc. Primary endpoint: Objective Response Rate. Started Jul 2002; status: completed.
02
Drugs
canfosfamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00040638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040638.